DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
CAMBRIDGE, Mass., Feb. 27, 2018 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, March 6th, 2018, at 5:00 p.m. ET to discuss a corporate update and results for the fourth quarter and full year of 2017.
To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 2449529. A live webcast of the presentation will be available on the Investors & Media section of the Editas website.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts
Media:
Cristi Barnett
(617) 401-0113
[email protected]
Investors:
Mark Mullikin
(617) 401-9083
[email protected]
